Diabetes Mellitus and Prostate Cancer Risk; A Nationwide Case–Control Study within PCBaSe Sweden
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: Diabetes mellitus (DM) increases the risk for cancer at almost all sites, but data on the association with prostate cancer are inconsistent. Methods: We assessed the risk of a prostate cancer diagnosis among men with type 2 (T2)DM in a nationwide population-based case-control study including 44,352 men with prostate cancer identified through the Prostate Cancer data Base Sweden (PCBaSe) between 2002 and 2006 and 221,495 age-matched men from the general population. Results: Overall, the risk of prostate cancer among men with T2DM was lower than among men without T2DM [OR, 0.80; 95% confidence interval (CI), 0.76–0.85]. The risk decreased with longer disease duration and was observed across all tumor risk categories, although most clearly among men with low risk tumors (OR, 0.71; 95% CI, 0.64–0.80). The risk for prostate cancer was reduced among diabetic men on dietary treatment only (OR, 0.89; 95% CI, 0.80–0.99) but more markedly among men on oral hypoglycemic agents (OR, 0.80; 95% CI, 0.74–0.87) and insulin (OR, 0.72; 95% CI, 0.69–0.81). Obese diabetic men (BMI > 30 kg/m2) showed a reduced risk (OR, 0.72; 95% CI, 0.65–0.80) compared with men without diabetes. There was a trend of decreasing risk with increasing levels of HbA1c (P < 0.05). Conclusions: This nationwide study confirmed a reduced risk of being diagnosed with prostate cancer among men with T2DM, especially for low-risk tumors. An altered hormonal milieu is a plausible explanation, although the possibility of decreased prostate cancer detection among diabetic men cannot be ruled out. Impact: This is the largest study to examine the association between T2DM and prostate cancer accounting for tumor risk group and diabetes treatment. Cancer Epidemiol Biomarkers Prev; 22(6); 1102–9. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Hoelzel, W., Weykamp, C., Jeppsson, J.-O., Miedema, K., Barr, J. R., Goodall, I., Hoshino, T., John, W. G., Kobold, U., Little, R., et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.024802 · Cited by 690
A meta-analysis of diabetes mellitus and the risk of prostate cancer
Kasper, J. S., & Giovannucci, E. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0410 · Cited by 491
Ma, J., Li, H., Giovannucci, E., Mucci, L., Qiu, W., Nguyen, P. L., Gaziano, J. M., Pollak, M., & Stampfer, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70235-3 · Cited by 421 · cited 1×
“Elevated C-peptide levels, reflecting serum insulin concentrations, have been associated with high-risk prostate cancer (11, 34) as well as prostate cancer–specific death (35).”
BackgroundLima, N., Cavaliere, H., Knobel, M., Halpern, A., & Medeiros-Neto, G. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801406 · Cited by 130 · cited 1×
“Additional influence of an altered hormonal milieu in obese men with low testosterone levelsmay speculatively explain this observation (42).”
Background
Cited by
Epidemiology of Prostate Cancer
Rawla, P. (2019) · World Journal of Oncology · doi:10.14740/wjon1191 · Cited by 2,776
on behalf of the Diabetes and Cancer Research Consortium, Carstensen, B., Read, S. H., Friis, S., Sund, R., Keskimäki, I., Svensson, A.-M., Ljung, R., Wild, S. H., Kerssens, J. J., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3884-9 · Cited by 180
Diabetes and cancer: Epidemiological and biological links
Wang, M., Yang, Y., & Liao, Z. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i6.227 · Cited by 158
Sharma, N., Khatib, M. N., Balaraman, A. K., Roopashree, R., Kaur, M., Srivastava, M., Barwal, A., Prasad, G. V. S., Rajput, P., Syed, R., et al. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04266-4 · Cited by 21
Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression
Papachristodoulou, A., Heidegger, I., Virk, R. K., Di Bernardo, M., Kim, J. Y., Laplaca, C., Picech, F., Schäfer, G., De Castro, G. J., Hibshoosh, H., et al. (2024) · European Urology · doi:10.1016/j.eururo.2023.07.016 · Cited by 18
Metadata
- Authors
- Fall, K., Garmo, H., Gudbjörnsdottir, S., Stattin, P., & Zethelius, B.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2013-06-01
- Volume
- 22
- Issue
- 6
- Pages
- 1102-1109
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2155774473
- Cited by
- 75
- References
- 5
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetes Mellitus and Prostate Cancer Risk; A Nationwide Case–Control Study within PCBaSe Sweden. https://app.cochat.ai/papers/10.1158/1055-9965.epi-12-1046
- The paper
- Fall, K., Garmo, H., Gudbjörnsdottir, S., Stattin, P., & Zethelius, B. (2013). Diabetes Mellitus and Prostate Cancer Risk; A Nationwide Case–Control Study within PCBaSe Sweden. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-12-1046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.